S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:MEDP

Medpace (MEDP) Stock Forecast, Price & News

$242.15
-2.55 (-1.04%)
(As of 09/26/2023 ET)
Compare
Today's Range
$242.15
$248.23
50-Day Range
$240.81
$281.67
52-Week Range
$146.05
$282.73
Volume
182,143 shs
Average Volume
335,691 shs
Market Capitalization
$7.40 billion
P/E Ratio
28.93
Dividend Yield
N/A
Price Target
$264.33

Medpace MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
9.2% Upside
$264.33 Price Target
Short Interest
Healthy
4.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.10mentions of Medpace in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$93.18 M Sold Last Quarter
Proj. Earnings Growth
16.09%
From $8.39 to $9.74 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

112th out of 964 stocks

Commercial Physical Research Industry

4th out of 14 stocks


MEDP stock logo

About Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

MEDP Price History

MEDP Stock News Headlines

Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
3 Top Stocks Exhibiting Superb Earnings Growth
Medpace (NASDAQ: MEDP)
Q2 2023 Medpace Holdings Inc Earnings Call
Medpace: Q2 Earnings Snapshot
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Company Calendar

Last Earnings
7/24/2023
Today
9/26/2023
Next Earnings (Estimated)
10/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEDP
Employees
5,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$264.33
High Stock Price Forecast
$273.00
Low Stock Price Forecast
$250.00
Forecasted Upside/Downside
+8.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$245.37 million
Pretax Margin
18.97%

Debt

Sales & Book Value

Annual Sales
$1.46 billion
Cash Flow
$8.62 per share
Book Value
$12.42 per share

Miscellaneous

Free Float
22,708,000
Market Cap
$7.44 billion
Optionable
Optionable
Beta
1.37
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. August James Troendle M.D. (Age 67)
    Chairman & CEO
    Comp: $1.68M
  • Mr. Jesse J. Geiger BBAMr. Jesse J. Geiger BBA (Age 49)
    CPA, Pres
    Comp: $876.92k
  • Mr. Kevin M. BradyMr. Kevin M. Brady (Age 48)
    CFO & Treasurer
    Comp: $636.58k
  • Ms. Susan E. Burwig BSN (Age 60)
    MA, Exec. VP of Operations
    Comp: $1M
  • Mr. Stephen P. Ewald J.D.Mr. Stephen P. Ewald J.D. (Age 54)
    Chief Compliance Officer, Gen. Counsel & Corp. Sec.
    Comp: $826.17k
  • Brandon Ebken
    Chief Information Officer
  • Ms. Lauren Morris
    Associate Director of Investors Relations
  • Mr. Todd Meyers
    VP of Bus. Devel. & Marketing
  • John T. Wynne MBA
    Sr. VP of Commercial Operations & Clinical Pharmacology Unit
  • Mr. Reinilde Heyrman M.D. (Age 62)
    Chief Medical Officer of Medical Department













MEDP Stock - Frequently Asked Questions

Should I buy or sell Medpace stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.
View MEDP analyst ratings
or view top-rated stocks.

What is Medpace's stock price forecast for 2023?

3 Wall Street analysts have issued 1 year price objectives for Medpace's stock. Their MEDP share price forecasts range from $250.00 to $273.00. On average, they anticipate the company's stock price to reach $264.33 in the next year. This suggests a possible upside of 8.6% from the stock's current price.
View analysts price targets for MEDP
or view top-rated stocks among Wall Street analysts.

How have MEDP shares performed in 2023?

Medpace's stock was trading at $212.41 at the start of the year. Since then, MEDP stock has increased by 14.6% and is now trading at $243.49.
View the best growth stocks for 2023 here
.

When is Medpace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, October 23rd 2023.
View our MEDP earnings forecast
.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) released its earnings results on Monday, July, 24th. The company reported $1.93 earnings per share for the quarter, beating the consensus estimate of $1.90 by $0.03. The company had revenue of $460.90 million for the quarter, compared to analysts' expectations of $433.75 million. Medpace had a trailing twelve-month return on equity of 72.88% and a net margin of 16.06%. The firm's quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.46 EPS.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY 2023 earnings guidance on Monday, July, 24th. The company provided EPS guidance of $8.04-$8.50 for the period, compared to the consensus estimate of $8.23. The company issued revenue guidance of $1.84 billion-$1.88 billion, compared to the consensus revenue estimate of $1.78 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.11%), Wasatch Advisors LP (5.13%), State Street Corp (2.20%), Riverbridge Partners LLC (2.14%), Boston Trust Walden Corp (1.80%) and Dimensional Fund Advisors LP (1.67%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends
.

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $243.49.

How much money does Medpace make?

Medpace (NASDAQ:MEDP) has a market capitalization of $7.44 billion and generates $1.46 billion in revenue each year. The company earns $245.37 million in net income (profit) each year or $8.37 on an earnings per share basis.

How many employees does Medpace have?

The company employs 5,200 workers across the globe.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444.

This page (NASDAQ:MEDP) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -